Magas vérnyomás: ki dolgozik rajta

Intézményenként egy kártya. Válassz célpontot, és csak az azon dolgozó csoportok maradnak.

• Minden célpont
• AMPK 0
• SGLT2 3
• GLP-1 2
• PPAR 0
• AKT 0
• NLRP3 0
• PI3K 0
• NRF2 1
• HIF-1 0
• STAT3 0
• VEGF 0
• ACE2 0
• SIRT1 0
• TNF 1
• IL-6 1
• mTOR 0
• TLR4 0
• ERK 0
• MAPK 0
• HMGB1 0
• YAP 0
• CXCR4 0
• HSP90 0
• IL-17 1
• AR 1
• PCSK9 3
• APOE 1
• CD19 0
• GPX4 0
• JNK 0
• METTL3 0
• PINK1 0
• PTEN 0
• TP53 0
• ABL1 0
• APOL1 0
• BTK 2
• CD40 0
• FAK 0
• HDAC 0
• IL-1 0
• JAK 0
• MMP-9 0
• PKM2 0
• STK11 0
• CGRP 0
• CTNNB1 0
• DPP-4 0
• FTO 0
• RUNX1 0
• STING 0
• AXL 0
• CD38 0
• COX-2 0
• DMD 0
• GIP 0
• HTT 0
• IDH 0
• IGF1R 0
• MDM2 0

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• European Commission (Horizon Europe) · HORIZON-ERC

  Selective Sensory Vagal Interface: a bionic platform for internal organ modulation (VisceraLink)

  Medizinische Universitaet Wien· Wien, Ausztria· EU contribution 2 210 625 EUR· until 2031. dec.

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Design and development of explainable DL/ML model for medical image analysis with high accuracy and reliability (MED-XAI)

  Universidade Nova de Lisboa· Lisboa, Portugália· EU contribution 207 183 EUR· until 2028. dec.

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Pulmonary Hypertension in COPD : from Observation to Emerging Novel therapeutic Insights and eXploration (PHOENIX)

  Universitat Zurich· Zurich, Svájc· EU contribution 292 119 EUR· until 2028. dec.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-GF

  Birth and Labor Outcome Optimization through Multimodal AI (BLOOM)

  Universita Degli Studi Gabriele D'annunzio di Chieti-Pescara· Chieti, Olaszország· EU contribution 321 949 EUR· until 2029. máj.· 3 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Unveiling Dynamic Autonomic Regulation in health and disease through Network Physiology (DARNePh)

  Univerzita Komenskeho V Bratislave· Bratislava 1, Szlovákia· EU contribution 172 942 EUR· until 2028. aug.· 2 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC

  Knowledge and Learning Integration Dynamic Open (KaLeIDO) Systems: a novel knowledge synthesis framework for globally informed and adaptive healthcare (KaLeIDO-CARE)

  Universitetet I Oslo· Oslo, Norvégia· EU contribution 1 998 381 EUR· until 2031. aug.

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-RIA

  COMMUNITY-BASED SCALE UP OF INTEGRATED COMMUNITY HEALTH WORKER-LED CARDIOVASCULAR RISK FACTOR MANAGEMENT - ComBaScale

  Instituut Voor Tropische Geneeskunde· Antwerpen, Belgium· EU contribution 3 999 621 EUR· until 2031. aug.· 6 countries

• European Commission (Horizon Europe) · HORIZON-ERC-POC

  NeoVena: A Bioresorbable Polymeric Venous Valve

  Universitat Zurich· Zurich, Svájc· EU contribution 150 000 EUR· until 2028. jan.

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-RIA

  Building Equitable Health Systems through Telemedicine and Community-Based Models for Hypertension and Diabetes Care (BEACON-HD)

  Technische Universitaet Muenchen· Muenchen, Németország· EU contribution 3 908 205 EUR· until 2030. máj.· 8 countries

• European Commission (Horizon Europe) · HORIZON-ERC-POC

  LOKI: Loiasis-associated chronic kidney disease – towards clinical recognition and policy action

  Institut de Recherche Pour Le Developpement· Marseille, Franciaország· EU contribution 150 000 EUR· until 2027. nov.

  The disease is named only in the funder's project summary, not in the title.

10 of 51 running projects, newest first. Listed amounts together: 231,7 M EUR.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Vizsgálatok, amelyek regiszteradata szerint az egyéni résztvevői adatokat (IPD) megosztják.

• Exploring the Effects of Antihypertensive and Lipid-Lowering Drugs on Inflammatory Cytokine Levels

  NCT06622304· Guangzhou Institute of Respiratory Disease· Forrás

Publikációk erről a betegségről egy MeSH-módszerkifejezés szerint, például szekvenálási vagy képalkotó módszerre.

• Single-Cell Analysis 12
• Organoids 1
• Mendelian Randomization Analysis 85
• CRISPR-Cas Systems 2
• Gene Expression Profiling 52
• Sequence Analysis, RNA 5
• Whole Genome Sequencing 2
• Exome Sequencing 10
• Proteomics 45
• Metabolomics 45
• Mass Spectrometry 3
• Flow Cytometry 4
• Immunohistochemistry 24
• Liquid Biopsy 1
• Xenograft Model Antitumor Assays 1
• Positron-Emission Tomography 6
• Magnetic Resonance Imaging 123
• Machine Learning 101
• Deep Learning 13
• Cohort Studies 415
• Genome-Wide Association Study 82

• CD38+ T-Cell Count Is an Immunologic Phenotype Associated With Blood Pressure.

  Hypertension, 2026. aug.

• Innate immune profiling reveals a specific reduction of CD57+CD62L+CD161+ NK cells in CMV-positive males with hypertension.

  Front Immunol, 2026. ápr.

• Abnormal Pro-inflammatory Immune Cell Responses Precede Clinical Onset of Hypertensive Disorders of Pregnancy.

  Hypertension, 2026. jan.

• Chronic administration of the probiotic kefir improves the endothelial function in spontaneously hypertensive rats.

  J Transl Med, 2015. dec.

Megmutatjuk, a betegség mely célpontjait említi az absztrakt, és onnan a rajtuk dolgozókhoz jutsz.